Canopy Growth Corp Asset Resilience Ratio
Canopy Growth Corp asset resilience ratio. Canopy Growth Corp (WEED) has an Asset Resilience Ratio of 0.45% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Canopy Growth Corp total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Canopy Growth Corp (2015–2026)
Asset resilience ratio of Canopy Growth Corp from 2015 to 2026. This chart shows how Canopy Growth Corp's Asset Resilience Ratio has changed over time. See WEED FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Canopy Growth Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Canopy Growth Corp's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$5.05 Million | 0.45% |
| Total Liquid Assets | CA$5.05 Million | 0.45% |
Asset Resilience Insights
- Limited Liquidity: Canopy Growth Corp maintains only 0.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Canopy Growth Corp Industry Peers by Asset Resilience Ratio
Compare Canopy Growth Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Canopy Growth Corp Asset Resilience Ratio by Year (2015–2026)
Canopy Growth Corp asset resilience ratio by year from 2015 to 2026. The table below shows the annual Asset Resilience Ratio data for Canopy Growth Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.45% | CA$5.05 Million ≈ $3.65 Million |
CA$1.12 Billion ≈ $809.27 Million |
-1.49pp |
| 2025-03-31 | 1.94% | CA$17.79 Million ≈ $12.87 Million |
CA$917.70 Million ≈ $663.85 Million |
-5.39pp |
| 2024-03-31 | 7.33% | CA$95.34 Million ≈ $68.97 Million |
CA$1.30 Billion ≈ $940.64 Million |
-5.79pp |
| 2023-03-31 | 13.13% | CA$320.14 Million ≈ $231.59 Million |
CA$2.44 Billion ≈ $1.76 Billion |
-2.92pp |
| 2022-03-31 | 16.05% | CA$900.97 Million ≈ $651.75 Million |
CA$5.62 Billion ≈ $4.06 Billion |
-11.25pp |
| 2021-03-31 | 27.30% | CA$1.86 Billion ≈ $1.35 Billion |
CA$6.82 Billion ≈ $4.94 Billion |
+8.39pp |
| 2020-03-31 | 18.91% | CA$1.30 Billion ≈ $938.17 Million |
CA$6.86 Billion ≈ $4.96 Billion |
-13.62pp |
| 2019-03-31 | 32.53% | CA$2.84 Billion ≈ $2.05 Billion |
CA$8.73 Billion ≈ $6.32 Billion |
+32.48pp |
| 2018-03-31 | 0.05% | CA$664.00K ≈ $480.33K |
CA$1.44 Billion ≈ $1.04 Billion |
-12.51pp |
| 2017-03-31 | 12.56% | CA$85.10 Million ≈ $61.56 Million |
CA$677.61 Million ≈ $490.17 Million |
+12.52pp |
| 2015-03-31 | 0.04% | CA$10.00K ≈ $7.23K |
CA$25.96 Million ≈ $18.78 Million |
-- |
About Canopy Growth Corp
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and … Read more